
CVS Health Corporation: shareholders and insiders
Price
$88.59
November 16, 2026Market cap $113B
What Ploutos Investor adds for CVS Health
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Nov 6, 2026, from their own Form 4 filings.
Bought on the market
$2.0M
1 person
Sold on the market
$324M
2 people
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $2.0M by 1 person·sold $324M by 2 people
- 2025: no buys, no sales
- 2026: bought $2.0M by 1 person, sold $324M by 2 people
- Nov 6, 2026Prem S ShahEVP and Group PresidentKind
- Jun 26, 2026James David ClarkSVP, Cont & Chief Acct OfficerKind
- May 31, 2026Brian NewmanEVP, Chief Financial OfficerKind
- May 31, 2026Amy Compton-PhillipsEVP, Chief Medical OfficerKind
- May 21, 2026Fernando AguirreDirectorKind
- May 21, 2026Larry RobbinsDirectorKind
- May 20, 2026Fernando AguirreDirectorKind
- May 20, 2026Larry RobbinsDirectorKind
- May 20, 2026Larry RobbinsDirectorKind
- May 20, 2026Larry RobbinsDirectorKind
- May 20, 2026Larry RobbinsDirectorKind
- May 19, 2026Larry RobbinsDirectorKind
- May 19, 2026Larry RobbinsDirectorKind
- May 8, 2026Tilak MandadiEVP, Chief Exp & Tech OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Prem S ShahEVP and Group President | 23.9K | $83.90 | $2.0M | Form 4 | |
| Jun 26, 2026 | James David ClarkSVP, Cont & Chief Acct Officer | 454 | $90.98 | $41.3K | Form 4 | |
| May 31, 2026 | Brian NewmanEVP, Chief Financial Officer | 2,478 | $90.98 | $225.4K | Form 4 | |
| May 31, 2026 | Amy Compton-PhillipsEVP, Chief Medical Officer | 7,618 | $90.98 | $693.1K | Form 4 | |
| May 21, 2026 | Fernando AguirreDirector | 1,563 | $93.50 | $146.1K | Form 4 | |
| May 21, 2026 | Larry RobbinsDirector | 370.5K | $93.45 | $35M | Form 4 | |
| May 20, 2026 | Fernando AguirreDirector | 30.4K | $93.78 | $2.9M | Form 4 | |
| May 20, 2026 | Larry RobbinsDirector | 797.6K | $93.48 | $75M | Form 4 | |
| May 20, 2026 | Larry RobbinsDirector | 152.7K | $94.81 | $14M | Form 4 | |
| May 20, 2026 | Larry RobbinsDirector | 66.9K | $95.67 | $6.4M | Form 4 | |
| May 20, 2026 | Larry RobbinsDirector | 800 | $96.28 | $77.0K | Form 4 | |
| May 19, 2026 | Larry RobbinsDirector | 1.98M | $94.45 | $187M | Form 4 | |
| May 19, 2026 | Larry RobbinsDirector | 151 | $95.18 | $14.4K | Form 4 | |
| May 8, 2026 | Tilak MandadiEVP, Chief Exp & Tech Officer | 69.6K | $89.58 | $6.2M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 21, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by CVS's officers and directors from 2006 up to November 16, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.30%
- Vanguard Capital ManagementShare of class7.51%
- Capital World InvestorsShare of class5.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.30% | 105M | Jul 16, 20252 filings since Apr 17, 2025 | 13G/A | |
| Vanguard Capital Management | 7.51% | 95.60M | Apr 29, 2026 | 13G | |
| Capital World Investors | 5.50% | 68.79M | May 13, 2025 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Fairfax Financial (Watsa)In the quarter
- Glenview CapitalIn the quarter-41%
- Viking Global (Halvorsen)In the quarter
- Renaissance TechnologiesIn the quarter+518%
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-11%
- Bridgewater (Dalio)In the quarter-29%
- Millennium Mgmt (Englander)In the quarter×11.1
- D.E. ShawIn the quarter-15%
- AQR CapitalIn the quarter+1.0%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Fairfax Financial (Watsa) | 2.71M | $281M | 10.63% | |
| Glenview Capital | 4.82M | -41% | $499M | 9.97% |
| Viking Global (Halvorsen) | 3.66M | $379M | 1.08% | |
| Renaissance Technologies | 2.72M | +518% | $233M | 0.32% |
| Point72 (Cohen) | 1.96M | $203M | 0.31% | |
| Citadel Advisors (Griffin) | 4.81M | -11% | $498M | 0.29% |
| Bridgewater (Dalio) | 441.0K | -29% | $46M | 0.19% |
| Millennium Mgmt (Englander) | 2.16M | ×11.1 | $224M | 0.15% |
| D.E. Shaw | 1.38M | -15% | $143M | 0.09% |
| AQR Capital | 2.41M | +1.0% | $249M | 0.09% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.27% of its shares outstanding were held short, -1.7% since the report before.
- Shares held short
- 16.19M
- 1.27%
- Since the report before16.47M on Sep 30, 2026
- -1.7%
- 1.6
- 10.33M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 21%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 15.87M
- Nov 15, 2023: Shares held short 15.84M
- Nov 30, 2023: Shares held short 15.58M
- Dec 15, 2023: Shares held short 14.84M
- Dec 29, 2023: Shares held short 16.45M
- Jan 12, 2024: Shares held short 42.52M
- Jan 31, 2024: Shares held short 36.79M
- Feb 15, 2024: Shares held short 30.76M
- Feb 29, 2024: Shares held short 24.17M
- Mar 15, 2024: Shares held short 18.64M
- Mar 28, 2024: Shares held short 22.72M
- Apr 15, 2024: Shares held short 18.00M
- Apr 30, 2024: Shares held short 13.71M
- May 15, 2024: Shares held short 11.37M
- May 31, 2024: Shares held short 17.71M
- Jun 14, 2024: Shares held short 20.64M
- Jun 28, 2024: Shares held short 18.43M
- Jul 15, 2024: Shares held short 17.82M
- Jul 31, 2024: Shares held short 19.99M
- Aug 15, 2024: Shares held short 17.42M
- Aug 30, 2024: Shares held short 18.50M
- Sep 13, 2024: Shares held short 17.40M
- Sep 30, 2024: Shares held short 19.75M
- Oct 15, 2024: Shares held short 20.80M
- Oct 31, 2024: Shares held short 21.85M
- Nov 15, 2024: Shares held short 21.39M
- Nov 29, 2024: Shares held short 17.77M
- Dec 13, 2024: Shares held short 19.03M
- Dec 31, 2024: Shares held short 18.10M
- Jan 15, 2025: Shares held short 16.99M
- Jan 31, 2025: Shares held short 21.35M
- Feb 14, 2025: Shares held short 23.60M
- Feb 28, 2025: Shares held short 20.55M
- Mar 14, 2025: Shares held short 19.88M
- Mar 31, 2025: Shares held short 18.26M
- Apr 15, 2025: Shares held short 18.65M
- Apr 30, 2025: Shares held short 16.43M
- May 15, 2025: Shares held short 15.90M
- May 30, 2025: Shares held short 15.45M
- Jun 13, 2025: Shares held short 18.71M
- Jun 30, 2025: Shares held short 16.02M
- Jul 15, 2025: Shares held short 13.67M
- Jul 31, 2025: Shares held short 15.65M
- Aug 15, 2025: Shares held short 16.66M
- Aug 29, 2025: Shares held short 18.80M
- Sep 15, 2025: Shares held short 23.62M
- Sep 30, 2025: Shares held short 18.94M
- Oct 15, 2025: Shares held short 19.52M
- Oct 31, 2025: Shares held short 18.90M
- Nov 14, 2025: Shares held short 19.29M
- Nov 28, 2025: Shares held short 19.63M
- Dec 15, 2025: Shares held short 22.92M
- Dec 31, 2025: Shares held short 21.67M
- Jan 15, 2026: Shares held short 18.76M
- Jan 30, 2026: Shares held short 20.35M
- Feb 13, 2026: Shares held short 16.53M
- Feb 27, 2026: Shares held short 17.58M
- Mar 13, 2026: Shares held short 17.81M
- Mar 31, 2026: Shares held short 19.89M
- Apr 15, 2026: Shares held short 18.35M
- Apr 30, 2026: Shares held short 17.81M
- May 15, 2026: Shares held short 19.52M
- May 29, 2026: Shares held short 17.76M
- Jun 15, 2026: Shares held short 23.19M
- Jun 30, 2026: Shares held short 19.94M
- Jul 15, 2026: Shares held short 19.52M
- Jul 31, 2026: Shares held short 18.68M
- Aug 14, 2026: Shares held short 16.82M
- Aug 31, 2026: Shares held short 18.11M
- Sep 15, 2026: Shares held short 16.12M
- Sep 30, 2026: Shares held short 16.47M
- Oct 15, 2026: Shares held short 16.19M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading24.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 24.5% of the shares in the reported trades were short sales, against 33.9% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 24.5%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 33.9%
- Change
- -9.4 pts
- Short sales a dayon average, of 5.29M shares
- 1.30M
- More than atof 3,668 US-listed companies, same days
- 2%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 22.4%
- Oct 9, 2026: Short sales 22.9%
- Oct 12, 2026: Short sales 21.6%
- Oct 13, 2026: Short sales 41%
- Oct 14, 2026: Short sales 27.1%
- Oct 15, 2026: Short sales 22%
- Oct 16, 2026: Short sales 35.4%
- Oct 19, 2026: Short sales 29.6%
- Oct 20, 2026: Short sales 58.6%
- Oct 21, 2026: Short sales 54%
- Oct 22, 2026: Short sales 46.5%
- Oct 23, 2026: Short sales 48.4%
- Oct 26, 2026: Short sales 44.3%
- Oct 27, 2026: Short sales 39.1%
- Oct 28, 2026: Short sales 23.1%
- Oct 29, 2026: Short sales 10%
- Oct 30, 2026: Short sales 20.6%
- Nov 2, 2026: Short sales 14.9%
- Nov 3, 2026: Short sales 17.4%
- Nov 4, 2026: Short sales 28.2%
- Nov 5, 2026: Short sales 12.7%
- Nov 6, 2026: Short sales 16.5%
- Nov 9, 2026: Short sales 23.9%
- Nov 10, 2026: Short sales 41.2%
- Nov 11, 2026: Short sales 45.3%
- Nov 12, 2026: Short sales 46.8%
- Nov 13, 2026: Short sales 31.6%
- Nov 16, 2026: Short sales 26.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Larry RobbinsDirectorDirectly–
- Prem S ShahEVP and Pres-Pharm, Consumer WDirectly88.5K
- Michael F MahoneyDirectorDirectly39.4K
- James David ClarkSVP, Cont & Chief Acct OfficerDirectly27.6K
- Anne A. FinucaneDirectorDirectly–
- Edward J LudwigDirectorDirectly21.6K
- Guy P SansoneDirectorDirectly12.0K
- Fernando AguirreDirectorDirectly10.5K
- Tilak MandadiEVP, Chief Exp & Tech OfficerDirectly10.1K
- Amy Compton-PhillipsEVP, Chief Medical OfficerDirectly9,557
- Brian NewmanEVP, Chief Financial OfficerDirectly3,008
- Heidi B CapozziEVP and Chief People OfficerDirectly–
- Steven H NelsonEVP and President, AetnaDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Larry RobbinsDirector | – | 4.82M | May 21, 2026 | Form 4 |
| Prem S ShahEVP and Pres-Pharm, Consumer W | 88.5K | – | Nov 6, 2026 | Form 4 |
| Michael F MahoneyDirector | 39.4K | – | Feb 18, 2025 | Form 4 |
| James David ClarkSVP, Cont & Chief Acct Officer | 27.6K | – | Jun 26, 2026 | Form 4 |
| Anne A. FinucaneDirector | – | 22.2K | Aug 20, 2025 | Form 4 |
| Edward J LudwigDirector | 21.6K | – | May 2, 2024 | Form 4 |
| Guy P SansoneDirector | 12.0K | – | Jun 5, 2025 | Form 4 |
| Fernando AguirreDirector | 10.5K | – | May 21, 2026 | Form 4 |
| Tilak MandadiEVP, Chief Exp & Tech Officer | 10.1K | – | May 8, 2026 | Form 4 |
| Amy Compton-PhillipsEVP, Chief Medical Officer | 9,557 | – | May 31, 2026 | Form 4 |
| Brian NewmanEVP, Chief Financial Officer | 3,008 | – | May 31, 2026 | Form 4 |
| Heidi B CapozziEVP and Chief People Officer | – | 85 | Oct 23, 2024 | Form 4 |
| Steven H NelsonEVP and President, Aetna | – | 24 | Jan 23, 2025 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$21M
Actually paid: $50M
$10M
Actually paid: $17M
$137
Peers: $148
Adjusted Earnings Per Share
From the proxy statement (DEF 14A) of Apr 3, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount–
- Mar 31, 202610-QAmount–
- Sep 30, 202510-QAmount–
- Jun 30, 202510-QAmount–
- Mar 31, 202510-QAmount–
- Sep 30, 202410-QAmount–
- Jun 30, 202410-QAmount–
- Mar 31, 202410-QAmount$3.0B
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | – | – | – | $11.5B | 10-Q |
| Mar 31, 202610-Q | – | – | – | $11.5B | 10-Q |
| Sep 30, 202510-Q | – | – | – | $11.5B | 10-Q |
| Jun 30, 202510-Q | – | – | – | $11.5B | 10-Q |
| Mar 31, 202510-Q | – | – | – | $11.5B | 10-Q |
| Sep 30, 202410-Q | – | – | – | $11.5B | 10-Q |
| Jun 30, 202410-Q | – | – | – | $11.5B | 10-Q |
| Mar 31, 202410-Q | 39.70M | $75.57 | $3.0B | $11.5B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund2.30%
- IXJiShares Global Healthcare ETFWeight in the fund1.71%
- VHTVanguard Health Care Index FundWeight in the fund1.65%
- VLUEiShares MSCI USA Value Factor ETFWeight in the fund1.54%
- SPYDState Street(R) SPDR(R) Portfolio S&P 500(R) High Dividend ETFWeight in the fund1.52%
- DVYiShares Select Dividend ETFWeight in the fund1.49%
- CGUSCapital Group Core Equity ETFWeight in the fund0.87%
- FNDXSchwab Fundamental U.S. Large Company ETFWeight in the fund0.79%
- MGVVanguard Morningstar Mega Cap Value Index FundWeight in the fund0.55%
- VYMVanguard High Dividend Yield Index FundWeight in the fund0.54%
42 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 1,841
- Q4 2025: Managers 1,951
- Q1 2026: Managers 1,883
- Q2 2026: Managers 2,069
Institutional investors by quarter
The fund managers holding CVS, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 2,069 managers held 1.14B shares, worth $118B. During the quarter 320 opened a position, 134 closed one, 757 added and 726 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-2.1%
- Vanguard Capital ManagementIn the quarter+0.8%
- Capital World InvestorsIn the quarter-3.0%
- State StreetIn the quarter+1.6%
- Dodge & CoxIn the quarter-3.4%
- Wellington Management GroupIn the quarter+50%
- Geode Capital ManagementIn the quarter+1.5%
- FMRIn the quarter-7.3%
- Vanguard Portfolio ManagementIn the quarter+2.5%
- Capital Research Global InvestorsIn the quarter+22%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 123M | -2.1% | $12.7B |
| Vanguard Capital Management | 83.32M | +0.8% | $8.6B |
| Capital World Investors | 74.95M | -3.0% | $7.8B |
| State Street | 60.28M | +1.6% | $6.2B |
| Dodge & Cox | 50.01M | -3.4% | $5.2B |
| Wellington Management Group | 33.80M | +50% | $3.5B |
| Geode Capital Management | 29.90M | +1.5% | $3.1B |
| FMR | 28.92M | -7.3% | $3.0B |
| Vanguard Portfolio Management | 26.64M | +2.5% | $2.8B |
| Capital Research Global Investors | 24.33M | +22% | $2.5B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do CVS Health's filings show?
Who buys and sells is one part of CVS Health's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CVS's insiders bought or sold?
From May 21, 2026 to Nov 6, 2026 CVS Health's insiders bought $2.0M and sold $317M of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold CVS?
10 of the managers we track held the shares on Sep 30, 2026. The largest position was Glenview Capital's, worth $499M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.